The American Heart Association (AHA) has compiled a series of evidence-based recommendations for the diagnosis, management, and treatment of cerebral venous thrombosis (CVT), and specifically for its management during pregnancy and postpartum, detailed in a statement published online Feb. 3 in Stroke.
FRIDAY, Feb. 4 (HealthDay News) -- The American Heart Association (AHA) has compiled a series of evidence-based recommendations for the diagnosis, management, and treatment of cerebral venous thrombosis (CVT), and specifically for its management during pregnancy and postpartum, detailed in a statement published online Feb. 3 in Stroke.
Gustavo Saposnik, M.D., from the University of Toronto, and colleagues from the AHA Stroke Council's Scientific Statement Oversight Committee, reviewed recent literature on CVT, a rare type of stroke, with a focus on published materials since 1966. The AHA levels-of-evidence grading algorithm was used to assess the evidence, and it formed the basis of their recommendations.
The researchers found increased incidences of CVT in women who are pregnant or taking oral contraceptives, and people aged 45 or younger. Women in the last trimester and up to four weeks after giving birth are also at high risk for CVT; up to 73 percent of CVTs in women occur in the immediate postpartum period. To diagnose and manage CVT, the committee recommends a blood test for prothrombotic factor for patients with suspected CVT, and screening patients for predisposing factors. The statement includes a process to assist clinicians with the diagnosis and management of CVT, including magnetic resonance imaging to confirm suspected CVT, coagulation therapy, and other options, such as surgery or endovascular treatment if necessary.
"Through a process of innovative research and systematic evaluation, diagnosis, management, and therapeutic alternatives will continue to evolve and consequently lead to better outcomes for patients with CVT," the authors write.
Several statement authors and reviewers disclosed financial relationships with the pharmaceutical industry.
Study shows a healthy prenatal diet could be upstream obesity prevention strategy
December 26th 2024"Our findings support the recommendation of a healthy diet based on the current guidelines (as measured by the HEI) during pregnancy, since it may reduce patterns of infant growth outside reference ranges."
Read More
S1E4: Dr. Kristina Adams-Waldorf: Pandemics, pathogens and perseverance
July 16th 2020This episode of Pap Talk by Contemporary OB/GYN features an interview with Dr. Kristina Adams-Waldorf, Professor in the Department of Obstetrics and Gynecology and Adjunct Professor in Global Health at the University of Washington (UW) School of Medicine in Seattle.
Listen
Early pregnancy cannabis use high in states with recreational legalization
November 11th 2024A population-based time-series analysis California before, during and after legalization show a rising trend in women using cannabis while pregnancy especially when the state has legalized the drug.
Read More
Similar delivery times between misoprostol dosages among obese patients reported
May 29th 2024A recent study found that obese patients undergoing induction of labor experienced similar delivery times regardless of whether they received 50 μg or 25 μg of vaginal misoprostol, though multiparous patients showed faster delivery with the higher dosage.
Read More